

Curriculum Vitae

(Last updated: 2017-02-06)

Young Kee Shin, M.D., Ph.D.

EDUCATION AND POSITIONS

2014-Present **Professor**, Department of Pharmacy, Seoul National University, Seoul, Korea
2016-Present **Professor**, Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
2013-Present **Vice President**, Bio-Max/N-Bio, Seoul National University, Seoul, Korea
2013-2016 **Head** of The Center for Anti-cancer Companion Diagnostics, Seoul National University, Seoul, Korea
2004-2014 **Assistant/Associate Professor** Department of Pharmacy, Seoul National University, Seoul, Korea
2001-2004 **Postdoctoral fellow** Department of Pathology, College of Medicine, Seoul National University, Seoul, Korea
1996-2000 **Ph.D.** Department of Pathology, College of Medicine, Seoul National University, Seoul, Korea
1990-1996 **M.D.** College of Medicine, Seoul National University, Seoul, Korea

HONOR AND PROFESSIONAL EXPERIENCE

2014-2016 **Expert adviser** of Central Pharmaceutical Affairs Council, Korea Food & Drug Administration
2011-Present **Evaluation committee member of intellectual property**, Korea Invention Promotion Association
2011-2013 **Medical equipment committee member**, Korea Food & Drug Administration
2006-2015 **Head of an Animal experiment center**, College of Pharmacy, Seoul national university
2005-2006 **Secretary General** of "The Pharmaceutical Society of Korea"
2005-2006 **Editorial Boards** of "Molecular & Cellular Toxicology ", **Standing Committee Member** of "Korean Society of Toxicogenomics and Toxicoproteomics"
2005-Present **IACUC (Institutional Animal Care and Use Committee) member**, Seoul National University, Seoul, Korea

PUBLICATION

1. Kim TE, Hong S, Song K, Park SH, **Shin YK**. Sensitization of glycoengineered interferon- β 1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy. *Oncotarget*. 2017 Jan 10. doi:10.18632/oncotarget.14573. [Epub ahead of print]
2. Lee JH, Kim SS, Lee HS, Hong S, Rajasekaran N, Wang LH, Choi JS, **Shin YK**. Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells. *Int J Oncol*. 2017 Jan;50(1):272-282. doi: 10.3892/ijo.2016.3793
3. Kim YJ, Hong S, Park MJ, Sung M, Jung KS, Noh KW, Oh DY, Lee MS, Oh E, **Shin YK**, Choi YL. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. *Oncotarget*. 2016 Dec 13;7(50):82876-82888. doi: 10.18632/oncotarget.12657.
4. Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HJ, Ni X, **Shin YK**, Johnson FM, Duvic M, Lee HY. Essential role of DNA methyltransferase 1-mediated transcription of insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. *Clin Cancer Res*. 2016 Aug 31. doi: 10.1158/1078-0432.CCR-16-0534. [Epub ahead of print]
5. Jeong HM, Lee S, Chae H, Kim RN, Kwon MJ, Oh E, Choi YL, Kim S, **Shin YK**. Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis. *Epigenomics*. 2016 Aug;8(8):1061-77. doi: 10.2217/epi-2016-0038

104 of publications (1998-Present)

PATENTS

Korea (24), PCT (8), USA (5), EP (3), JAPAN (3), Brazil (1), India (1), China (1)

ENTREPRENEURIAL EXPERIENCE

- Ministry of Food and Drug Safety (MFDS) approval for breast cancer prognosis diagnosis
- Development of bio-better version IFN β mutein
- Development of companion diagnostics (CDx)

WEBSITE

<http://www.snupharm.ac.kr/molpath/>